Multicenter Study of Circulating Tumor DNA in Patients With Pancreatic Cancer Using a Personalized Panel

Inclusion Criteria: A. Unresectable Pancreatic Cancer: 1. At least 20 years of age at the time of consent 2. Histopathologically confirmed adenocarcinoma and diagnosed as having ① or ② described below within 60 days prior to enrollment * Clinical Stage Ⅲ (T1-3N2M0, T4 anyNM0) * Clinical Stage Ⅳ (anyTanyNM1) 3. Scheduled to receive systemic chemotherapy for unresectable pancreatic cancer. 4. No prior treatment for pancreatic cancer 5. Willing to provide blood and tissue samples in accordance with the research protocol. 6. Adequate tissue samples are available 7. Written informed consent for participating in this study B. Resectable Pancreatic Cancer: 1. At least 20 years of age at the time of consent. 2. Tissue sample collected by EUS-FNA/FNB and histopathologically diagnosed as having adenocarcinoma. 3. Diagnosed as having cancer meet any one of a to d below within 60 days prior to enrollment 1. cStage IA (T1 N0 M0) 2. cStage IB (T2 N0 M0) 3. cStage IIA (T3 N0 M0) 4. cStage IIB (T1-3 N1 M0) 4. Scheduled to undergo surgery for resectable pancreatic cancer. 5. No history of prior treatment for pancreatic cancer. 6. Willing to submit blood and tissue samples in accordance with the research protocol. 7. Adequate tissue samples are available 8. Written informed consent for participating in this study Exclusion Criteria: Common exclusion criteria for both the unresectable and resectable pancreatic cancer patient cohorts: 1. Synchronous double/multiple cancer or metachronous double/multiple cancer with progression free period of 2 years or shorter. 2. Women who are pregnant or planning to become pregnant. 3. Judged by the investigator as being unsuitable for participation in the study.